Terumo Corporation announces that it has resolved at a meeting of the Board of Directors held on February 9, 2022 appointed Takayoshi Mimura as Director and Corporate Advisor and Toshiaki Takagi as chairman of the Board. Takayoshi Mimura, with completion of his term, is planned to leave the director's position at the Annual General Meeting of Shareholders to be held on June 22, 2022, and to remain as Corporate Advisor. Scheduled Date of Assuming Office is April 1, 2022.
Terumo Corp is a Japan-based company mainly engaged in the manufacture and sale of medical devices and pharmaceuticals. The Company operates in three segments. The Cardiovascular Company segment provides guidewires for angiography, catheters for angiography, introducer sheaths, coils, stents and bag embolization devices for treatment of cerebral aneurysms, artificial lungs and artificial heart-lung machines. The Medical Care Solutions Company segment provides hospital care solutions, life care solutions, and pharmaceutical solutions. The Blood and Cell Technology Company segment provides blood bags, component blood collection systems, automated blood product systems, pathogen reduction systems, and centrifugal blood component separators.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
